Burke William Mr. Buys Shares of Axogen, Inc.
Burke William Mr. acquired 4,392 shares of Axogen, Inc. on June 24, 2026.
Key Points
- Burke William Mr. bought 4,392 shares of Axogen, Inc. (AXGN) on June 24, 2026.
- Axogen, Inc. stock traded at $44.49 on Saturday with a market cap of $2.37 billion.
- Analysts maintain a buy rating with a target mean price of $50.78 for Axogen, Inc.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Burke William Mr. recently acquired 4,392 shares of Axogen, Inc. (NasdaqCM: AXGN) on June 24, 2026. The purchase did not specify a price or total value, but it adds to the insider activity for the company.
Insider Buying and Selling at Axogen, Inc.
Several insiders, including Burke William Mr., made similar purchases on June 24, 2026. Kathy Johnson Weiler, Joseph Tyndall, Paul Thomas, Amy McBride Wendell, and John Johnson each bought 4,392 shares, while Paul Thomas acquired 5,579 shares. None of these transactions were planned trades.
Axogen, Inc. Stock Down 12.7%
Shares of Axogen, Inc. traded near $44.49 on Saturday. The company, which specializes in medical devices for nerve repair, has a market cap of about $2.37 billion. It carries a forward P/E ratio of 61.1 and a beta of 1.12. The stock's 52-week range spans from $10.20 to $46.00, with a 50-day moving average of $41.31 and a 200-day moving average of $30.96. Axogen maintains a strong current ratio of 7.1 and a quick ratio of 5.0, though it operates with a debt-to-equity ratio of 8.4.
$AXGN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts are maintaining a positive outlook on Axogen, Inc. On April 29, 2026, Canaccord Genuity, Citizens, Wells Fargo, and HC Wainwright & Co. each reaffirmed their buy ratings, with price targets around $50. Lake Street held a buy rating with a similar target. The consensus target mean price sits at $50.78, based on nine analyst opinions.
About Axogen, Inc.
Axogen, Inc., headquartered in Alachua, Florida, is a healthcare company that focuses on developing and commercializing technologies for peripheral nerve repair. The company provides products like the Avance Nerve Graft and Axoguard Nerve Connector, which assist in nerve regeneration and repair. With a team of 622 employees, Axogen serves hospitals and surgery centers globally, targeting surgeons in various specialties.
Bottom Line
Insider buying at Axogen, Inc. suggests internal confidence in the company's future. The stock has been performing well, trading close to its 52-week high. Investors will be watching closely for the next earnings report on August 4, 2026, to see how the company continues to grow.
Get Axogen, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AXGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.